Drug Patents owned by Cti Biopharma Corp

1. Drug name - VONJO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153632 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
Jan, 2029

(6 years from now)

US8980873 CTI BIOPHARMA CORP 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Mar, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 28, 2027

Drugs and Companies using PACRITINIB CITRATE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in